Cellectis S.A.
CLLS · XNASCIK 1627281fmd_1CAZQXQVA4NT4KNAXND5BX81ARManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2014 to Dec 31, 2025, 20 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 45 | 25 | 13 | 15 | 51 | 30 | 19 | 1 | 42 | 73 |
| Cost of revenue | – | 3 | 3 | 11 | 2 | 2 | 2 | 1 | 0 | 0 |
| Gross profit | – | 23 | 10 | 4 | 49 | 29 | 17 | 0 | 42 | 73 |
| Research and development | 78 | 79 | 77 | 92 | 77 | 118 | 98 | 88 | 91 | 94 |
| Selling, general and administrative | 43 | 45 | 47 | 43 | 23 | 23 | 17 | 17 | 19 | 20 |
| Operating income | (67) | (93) | (105) | (124) | (42) | (103) | (90) | (97) | (60) | (33) |
| Interest expense | 7 | 18 | 4 | 4 | 16 | 6 | 18 | 41 | 22 | 51 |
| Income before taxes | (67) | (104) | (88) | (115) | (54) | (97) | (99) | (116) | (37) | (68) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (0) |
| Net income from continuing operations | (67) | (104) | (88) | (115) | (54) | (97) | (99) | (117) | (37) | (68) |
| Net income | (67) | (99) | (79) | (102) | (81) | (114) | (106) | (101) | (37) | (68) |
| Net income to common shareholders | (0) | (99) | (79) | (102) | (81) | (114) | (106) | (101) | – | – |